@article{5c6d7e5e53d94af49abdd1ab4ee1dd01,
title = "Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study",
abstract = "Objective: To explore feasibility of measuring tumor blood flow as marker for antiangiogenic activity using DCE-MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging) in women with recurrent EOC/PPC treated with bevacizumab. Methods: In a phase II study, 62 patients with recurrent/persistent EOC/PPC were treated with bevacizumab (15 mg/kg IV q21days) until disease progression. DCE-MRI was performed pre-cycle 1 and 4 of bevacizumab. Images were analyzed retrospectively by a single experienced blinded radiologist. Tumor and muscle contrast enhancement was measured by region of interest signal intensity within the same DCE-MRI images. Flow rates were obtained with concentration of dye as a function of time. Relative blood flow (RBF) was calculated as a ratio of average blood flow into tumor to muscle tissue. Associations between RBF and characteristics/outcomes were explored. Results: Sixty-two patients were eligible for study. Unfortunately, only 14 (23%) patients had imaging data available for analysis at baseline and 13 of those same patients (21%) had imaging data available for analysis pre-cycle 4. The RBF distribution was similar from pre-cycle 1 to 4. RBF remained stable for the majority of the cases (median change -0.21). Baseline RBF was not significantly associated with being progression-free at 6 months, microvessel density, 17 month overall survival, tumor response, or platinum sensitivity. However, increases in blood flow rates were associated with likelihood to be progression-free at 6 months. Conclusion: Functional imaging of tumor blood flow is a potential research endpoint that may be explored further. Consideration should be given to timing of endpoint and standardizing the technique.",
keywords = "Dynamic contrast-enhanced magnetic resonance imaging, GOG, Primary peritoneal cancer",
author = "Chase, {Dana M.} and Sill, {Michael W.} and Monk, {Bradley J.} and Chambers, {Mark D.} and Darcy, {Kathleen M.} and Han, {Ernest S.} and Buening, {Barbara J.} and Sorosky, {Joel I.} and Fruehauf, {John P.} and Burger, {Robert A.}",
note = "Funding Information: Data from this study was presented in part at the 2011 meeting of the Society of Gynecologic Oncologists, March 6-9, 2011 in Orlando, FL. All authors meet the criteria for authorship, have approved the final version, and agree to transfer copyright to the Gynecol Oncol should the manuscript be accepted.This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical and Data Center (CA 37517), as well as a National Institutes of Health K-23 grant to the primary and corresponding author (RAB). The following Gynecologic Oncology Group member institutions participated in this study:University of Washington/Puget Sound Oncology; Johns Hopkins Oncology Center; North Shore University Hospital; University of Iowa Hospitals and Clinics; St. Vincent Hospital and Health Care Center; University of California Medical Center at Irvine; University of Alabama at Birmingham; Washington Hospital Center; Franklin Square Hospital Center; Methodist Cancer Center; UCSF - Stanford Health Systems; University of Kansas Medical Center; Columbus Cancer Council/Ohio State; Rapid City Regional Oncology Group; Kaiser Permanente, Los Angeles Medical Group; British Columbia Cancer Agency; Mount Carmel Health Center; University of Calif. at Los Angeles (UCLA); Cancer Center of Santa Barbara. ",
year = "2012",
month = sep,
doi = "10.1016/j.ygyno.2012.06.002",
language = "English",
volume = "126",
pages = "375--380",
journal = "Gynecologic Oncology",
issn = "0090-8258",
number = "3",
}